Biomarkers for precision oncology: challenges, platforms and regulatory considerations
Technological advancement and the discovery of various biomarkers have made personalized/precision medicine a reality. Biomarkers are measurable indicators of biological processes and can be used to diagnose cancer, determine prognosis and monitor response to therapy. In this precision oncology era, more and more clinical trials are now driven by biomarkers, with an overarching objective to optimize and personalize disease management.
The inclusion of companion biomarkers has become mandatory in all new drug trials that are conducted for targeted therapies in the oncological field. By identifying specific biomarkers, researchers can develop more effective treatments that are tailored to individual patients. This approach has the potential to revolutionize cancer treatment and improve patient outcomes.
What will you learn?
- Challenges and regulation considerations in biomarker bioanalysis
- Current technologies and analytical platforms used for biomarker discovery
- Disease biomarkers in oncology drug development and personalized medicines
Who may this interest?
- Biomarker and bioanalytical scientists
- Pharmaceutical professionals
- Translational medicine professionals
Speaker
Jialu Liu
Associate Director, Biologics Services
Frontage Laboratories, Inc. (PA, USA)
Dr Jialu Liu is an Associate Director and subject matter expert for the Biomarker Services team at Frontage Laboratories, providing scientific leadership and contributing to the development of the global biomarker strategy. He works as a liaison between business operations, development, and various other departments, and has been involved with communicating and presenting biomarker bioanalysis capabilities to biopharma sponsors. He also leads the biomarker method development team for new LBA method development, transfer and validation projects at Frontage.
This webinar was recorded on Thursday 14 September 2023.
In association with
